The liquid biopsy functional genomics company OncoDxRx claims their exclusive technology PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) is the world-first and most powerful in the market with unmatched high levels of accuracy.

OncoDxRx said in a statement: “The instrumented coverage of PGA is over 700 anticancer drugs. It's extremely high throughput, fast turnaround and low cost at the same time, which is quite unique, which means it can be easily implemented and operated in most labs.”

The company stated “It's extremely modern as a highly personalized test. PGA can map out the best drugs or combinations to significantly broaden the treatment options for individual patients.”

“PGA is perfectly complementary to the existing NGS-based biomarker testing in precision oncology. PGA could benefit those patients disqualified by NGS, and provide them with alternative therapy options. And it has the ability to deal with patients when standard-of-care has been exhausted, for example, those refractory, metastatic or relapsed cases.”

“In the global markets, PGA is the first and the only drug response prediction test for patient non-responders in the world.”

“Today there is no equivalent or similar technology exists. Nothing. Period,” OncoDxRx said.